Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years

T Kalincik; I Diouf; S Sharmin; C Malpas; T Spelman; D Horakova; EK Havrdova; M Trojano; G Izquierdo; A Lugaresi; A Prat; M Girard; P Duquette; P Grammond; V Jokubaitis; A Van Der Walt; F Grand'maison; P Sola; D Ferraro; V Shaygannejad; R Alroughani; R Hupperts; M Terzi; C Boz; J Lechner-Scott; E Pucci; V Van Pesch; F Granella; R Bergamaschi; D Spitaleri; M Slee; S Vucic; R Ampapa; P McCombe; C Ramo-Tello; J Prevost; J Olascoaga; E Cristiano; M Barnett; ML Saladino; JL Sanchez-Menoyo; S Hodgkinson; C Rozsa; S Hughes; F Moore; C Shaw; E Butler; O Skibina; O Gray; A Kermode; T Csepany; B Singhal; N Shuey; I Piroska; B Taylor; M Simo; CA Sirbu; A Sas; H Butzkueven; G Iuliano; T Petersen; F Verheul; N Vella; K Kovacs; T Petkovskaboskova; T Erdelyi; E Dobos; RF Bolaños; I Kister; JA Cabrera-Gomez; E Roullet; C Zwanikken; L Den Braber-Moerland; N Der; A Firstenfeld; EA Bacile; V Santiago; C Vrech S; T Hardy; WO Arruda; S Charest; C Oreja-Guevara; G McDonnell; G Rum; S Flechter; D Khurana; MP Amato; V Bojkovski; E Van Munster; ME Rio; T Al-Harbi; J Haartsen

Journal article

Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years

T Kalincik, I Diouf, S Sharmin, C Malpas, T Spelman, D Horakova, EK Havrdova, M Trojano, G Izquierdo, A Lugaresi, A Prat, M Girard, P Duquette, P Grammond, V Jokubaitis, A Van Der Walt, F Grand'maison, P Sola, D Ferraro, V Shaygannejad Show all

Neurology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2021

DOI: 10.1212/WNL.0000000000011242

Abstract

Objective To test the hypothesis that immunotherapy prevents long-term disability in relapsing-remitting multiple sclerosis (MS), we modeled disability outcomes in 14,717 patients. Methods We studied patients from MSBase followed for ≥1 year, with ≥3 visits, ≥1 visit per year, and exposed to MS therapy, and a subset of patients with ≥15-year follow-up. Marginal structural models were used to compare the cumulative hazards of 12-month confirmed increase and decrease in disability, Expanded Disability Status Scale (EDSS) step 6, and the incidence of relapses between treated and untreated periods. Marginal structural models were continuously readjusted for patient age, sex, pregnancy, date, dis..

View full abstract

University of Melbourne Researchers

Tomas Kalincik Author

Ibrahima Diouf Author

Sifat Sharmin Author

Charles Malpas Author

Related Projects (2)

PRECISION TREATMENT FOR MULTIPLE SCLEROSIS: MAXIMISING THE EFFECT OF IMMUNOMODULATORY THERAPY

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

PRECISION THERAPY FOR NEUROLOGICAL DISEASES

Multiple sclerosis is the most common cause of neurological disability among young adults. The patients’ individual response to therapy is h..

Grants

Awarded by National Health and Medical Research Council

Funding Acknowledgements

This study was financially supported by National Health and Medical Research Council of Australia (1129189, 1140766, 1080518) and Biogen (research grant 2016003-MS). The MSBase Foundation is a not-for-profit organization that receives support from Roche, Merck, Biogen, Novartis, BayerSchering, Sanofi-Genzyme, and Teva. The study was conducted separately and apart from the guidance of the sponsors.